Published on 24 Oct 2022 on The Business Journals
Drug maker Myovant to go private in $1.7 billion deal driven by Sumitomo Pharma - San Francisco...
Myovant's board had rejected an earlier bid, but a sweetened offer drew a different response.
Asia Deal Digest: Sullivan & Cromwell, Skadden, Latham, Allen & Gledhill Gain With Billion-Dollar...
These deals were spread across Asia, taking place in Japan, Singapore, Mainland China, Taiwan,...
Deal Watch: Twitter Deal Is Done, but the Legal Work Likely Isn't | The American Lawyer
While Elon Musk closed the $44 billion Twitter deal, the work from lawyers may be far from over....
Myovant Sciences shares trading higher after agreeing to Sumitomo deal for $2.9 billion
Shares of Myovant Sciences Ltd. were up 8.2% in premarket trading on Monday, the day after the co...
Myovant Sciences: Fiscal Q2 Earnings Snapshot
LONDON (AP) _ Myovant Sciences Ltd. (MYOV) on Wednesday reported a loss of $45.6 million...
Peninsula drug company Myovant to go private in $1.7 billion buyout
A company led by former Genentech Inc. president Myrtle Potter will buy part of Brisbane-based dr...
Drug maker Myovant to go private in $1.7 billion deal driven by Sumitomo Pharma - San Francisco...
Myovant's board had rejected an earlier bid, but a sweetened offer drew a different response.
Sumitomo Unit Agrees to Buy Myovant After Increasing Offer
(Bloomberg) -- A fully-owned subsidiary of Sumitomo Pharma Co. agreed to buy the rest of drugmake...
Myovant Sciences shares trading higher after agreeing to Sumitomo deal for $2.9 billion
Shares of Myovant Sciences Ltd. were up 8.2% in premarket trading on Monday, the day after the co...
Myovant Sciences: What The Sumitomo Offer Foretells (NYSE:MYOV)
One of the most exciting times in biotech investing is when a company received an offer from a...
Sumitomo Offers to Buy All of Myovant in $2.5 Billion Deal
(Bloomberg) -- A fully-owned subsidiary of Sumitomo Pharma Co. offered to buy the remaining outst...